Provided by Tiger Trade Technology Pte. Ltd.

Bright Minds Biosciences Inc

75.97
+2.893.95%
Post-market: 75.970.00000.00%16:21 EST
Volume:116.45K
Turnover:8.91M
Market Cap:739.36M
PE:-71.91
High:77.75
Open:74.79
Low:74.63
Close:73.08
52wk High:123.75
52wk Low:23.18
Shares:9.73M
Float Shares:5.24M
Volume Ratio:0.78
T/O Rate:2.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0565
EPS(LYR):-1.2765
ROE:-27.93%
ROA:-18.80%
PB:12.33
PE(LYR):-59.51

Loading ...

BTIG Sticks to Its Buy Rating for Bright Minds Biosciences (DRUG)

TIPRANKS
·
Feb 03

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

GlobeNewswire
·
Jan 10

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

GlobeNewswire
·
Jan 08

Crude Oil Down 2%; ISM Services PMI Surges In December

Benzinga
·
Jan 08

Press Release: Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Dow Jones
·
Jan 07

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Benzinga_recent_news
·
Jan 07

Bright Minds Biosciences Up Over 24%, on Track for Record High Close -- Data Talk

Dow Jones
·
Jan 07

Bright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure

MT Newswires Live
·
Jan 06

U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure

Reuters
·
Jan 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 18, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 15, 2025

Press Release: Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

Dow Jones
·
Nov 17, 2025

Bright Minds Biosciences to Present at Upcoming Conferences

GlobeNewswire
·
Oct 31, 2025

Bright Minds Biosciences Inc : Btig Initiates Coverage With Buy Rating; Target Price $72

THOMSON REUTERS
·
Sep 08, 2025

Bright Minds Biosciences Enters Deal for $100 Million At-The-Market Offering

MT Newswires Live
·
Sep 05, 2025

Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model

GlobeNewswire
·
Sep 04, 2025

Bright Minds Biosciences to Present at Upcoming Conferences

GlobeNewswire
·
Aug 25, 2025